echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qinhao Pharmaceutical's SHP2 inhibitor was approved for clinical use

    Qinhao Pharmaceutical's SHP2 inhibitor was approved for clinical use

    • Last Update: 2021-12-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    On November 10, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that the Class 1 new drug GH21 capsules declared by Qin Hao Medicine had obtained the implied license for clinical trials and planned to be developed for advanced solid tumors


    Screenshot source: CDE official website

    The full name of SHP2 is a protein tyrosine phosphatase containing Src homology 2 domain


    According to Qinhao Pharmaceutical’s earlier press release, GH21 is a small molecule anti-tumor drug with great potential for development.


    In September 2020, Qinhao Pharmaceutical and Huya Bio-International reached an exclusive license agreement, granting the latter the right to develop and commercialize GH21 products outside of China


    Reference materials:

    [1] Drug Evaluation Center of China National Medical Products Administration.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.